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Abstract 
Lena Olsén 2007. Drugs in horses: pharmacokinetics and pharmacodynamics  
Doctoral thesis ISSN 1652-6880, ISBN978-91-576-7336-7 
 
In this thesis the fate and effect of some drugs have been examined in horses. Studies have 
also been performed to explore some factors which may affect the pharmacokinetics and the 
pharmacodynamics of drugs in horses. 
Investigations  on  the  drug  metabolising  enzyme  cytochrome  P450  3A  (CYP3A)  in  the 
intestines of horses showed high gene expression and metabolic activity in the proximal 
parts of the intestines. The results indicate that CYP3A in the intestines of horse plays a 
major role in the first-pass metabolism of drugs which are substrates for CYP3A. 
There is a need for an antihistamine for oral therapy of horses. The oral bioavailability of 
the antihistamine fexofenadine was found to be low, and this drug is therefore unsuitable for 
oral use in horses. In contrast oral administration of the antihistamine cetirizine resulted in a 
sufficient uptake. This drug was also found to have a potent antihistaminic effect in horses. 
Cetirizine may therefore be a suitable antihistamine in equine medicine.  
The passage of antihistamines, such as fexofenadine and cetirizine, as well as several 
other xenobiotics, over cell-membranes in various tissues is partly regulated by transport 
proteins. Studies in this thesis showed that pre-treatment of horses with the antiparasitic 
agent ivermectin affects the oral bioavailability of fexofenadine and cetirizine. The effect of 
ivermectin is probably related to interference in the function of the transport proteins. 
Acute  adverse  reactions  may  occur  following  treatments  of  horses  with  procaine 
benzylpenicillin  or  potassium  or  sodium  benzylpenicillin.  Analysis  of  adverse  reactions 
reported in 59 horses indicates that allergy may underlie a few of the cases. However, most 
reactions may be due to toxic effects of procaine. Several mechanisms may contribute to the 
procaine toxicity. It was shown that the ability of plasma esterases to hydrolyze procaine to 
non-toxic  metabolites  was  lower  in  reacting  horses  compared  to  non-reacting  control 
horses. Low plasma esterase activity may increase the likelihood for procaine toxicity and 
constitute one risk factor. 
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Abbreviations  
   
ATP                adenosine triphosphate 
AUC                area under the plasma concentration time curve  
AUMC               area under the first moment curve 
b.w.                 body weight 
cDNA               complementary DNA 
Cl                  clearance 
Cmax                 the maximal plasma concentration 
CYP                cytochrome P450 
DFB    3-(3,4-difluorobenzyloxy)-5,5-dimethyl-4-(4-
methylsulfonylphenyl)-5H-furan-2-one 
DFH    3-hydroxy-5,5-dimethyl-4-(4-methylsulfonylphenyl)-5H-furan-2-
one 
DNA                deoxyribonucleic acid 
Emax                 the maximal effect  
EC50                the plasma concentration producing 50 % of the maximal effect  
F                   bioavailability 
HPLC               high-performance liquid chromatography 
IgE                  immunoglobulin of type E 
i.m.                 intramuscular 
i.v.                  intravenous 
Ke0   the  rate  constant  for  the  elimination  of  drug  from  the  effect 
compartment 
LC-ESI-MS/MS   liquid  chromatography  electrospray  ionisation  tandem  mass 
spectrometry 
MDR1               multidrug resistance gene 1 
mRNA              messenger RNA 
MRT                mean residence time 
NADP               nicotinamide adenine dinucleotide phosphate 
NSAID              non-steroidal anti-inflammatory drugs 
OATP               organic anion transport polypeptide 
PABA               para-aminobenzoic acid 
pH    negative logarithm of the hydrogen ion concentration of an aqueous 
solution 
PD                  pharmacodynamics   
P-gp                permeability-glycoprotein 
PK                  pharmacokinetics 
pK                  negative logarithm in an equilibrium constant; pKa for acids 
p.o.                 oral  
Real-time RT-PCR    real time reversed transcription polymerase chain reaction 
RNA                ribonucleic acid 
s.c.                  subcutaneous 
ss                   steady state 
Tmax                 time to obtain the maximal plasma concentration 
t½                   half-life 
Vd                  volume of distribution  
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 Introduction 
Background 
Knowledge about the factors, which determine the fate of drugs in the body is 
essential in order to get the right drug and dosage schedules and also to avoid toxic 
effects. Right doses mean that the horse will receive maximum benefit, in terms of 
optimal efficacy with minimal toxicity. Correct drug dosing will contribute a lot to 
the animal’s welfare. 
 
Horses, like other animals, have evolved complex systems that detoxify foreign 
chemicals, such as toxins present in poisonous plants. As concern the mechanisms 
by  which  the  body  handles  foreign  compounds,  there  is  no  difference  between 
drugs and other xenobiotics. In order to exert their effects, drugs need to achieve 
adequate concentrations in the target tissue(s). Drug concentrations in the body is 
depending on the drug disposition, which in turn, is depending on the absorption 
from the site of administration, the distribution within the body, the metabolism 
and the excretion. 
 
Oral administration is a convenient way to deliver a drug, but this route also has 
considerable  challenges.  Drug  absorption  from  the  gastrointestinal  tract  is  a 
complex  process affected by factors such as the rate of stomach emptying, the 
intestinal  motility,  the  environment  in  the  intestinal  lumen,  the  structure  of  the 
intestinal mucosa and the presence and distribution of metabolising enzymes and 
drug transport proteins in the intestinal wall and liver. When the drug molecule 
reaches  the  bloodstream,  the  cardiovascular  system  provides  a  very  fast  long-
distance bulk flow distribution arrangement. The way in which drugs cross the cell 
membranes  differ  markedly  between  different  drugs  due  to  their  chemical  and 
physical properties. This transfer is difficult to predict and is depending of several 
factors such as chirality, solubility, lipophilicity, pKa, hydrogen bonding capacity, 
molecular size and weight. The transport of drugs across cell-membranes may also 
be regulated by transport proteins. Such processes are especially important in the 
renal tubules, the biliary tract, and the gastrointestinal mucosa and at the blood-
brain barrier. 
 
Drug elimination is the irreversible loss of drug from the body and occurs by 
metabolism and excretion. The rate of the metabolism is one important factor that 
determines both the concentrations and durations of the drug in the body. A large 
number of enzymes are involved in the metabolism of drugs. The liver plays a 
major  role  in  the  first-pass  metabolism  of  orally  administered  drugs  and  also 
regulates  the  systemic  drug  levels.  High  levels  of  metabolising  enzymes  are 
expressed  also  in  several  other  tissues.  Thus,  metabolism  in  the  intestinal 
epithelium may contribute to the first-pass metabolism of drugs. Drug metabolism 
in other extrahepatic tissues can lead to alteration of the efficacies of drugs by 
inactivation of active drugs or by activation of prodrugs but usually has limited 
influence of the overall elimination rate. Several compounds that cause toxicity are 
metabolically  activated  to  reactive  intermediates  that  bind  to  tissue  
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macromolecules locally in the tissues in which the metabolism takes place. Drugs 
may  also  interact  on  a  chemical-physical,  physiological,  pharmacodynamical  or 
pharmacokinetical basis, which in turn can lead to unwanted or no effects of the 
drug.  
 
The  excretion  occurs  mainly  via  bile  and  urine.  In  the  liver  drugs  or  drug-
metabolites are excreted into bile and are then eliminated via faeces. Urinary drug-
excretion  is  depending  on  glomerular  filtration  as  well  as  active  and  passive 
secretion and absorption processes in the renal tubular epithelium. 
 
The fate of drugs in the body  
Understanding the mechanisms of drug action and exposure-response relationships 
are critical for dose selection. For the determination of the optimal dosing regimen, 
including dose, dosing interval and duration of treatment a dose-titration study is 
often used either in animal models or in in vitro systems. To assess this different 
pharmacokinetic  (PK)  parameters  are  used  as  tools.  The  goal  is  to  obtain 
appropriate efficacy in the treated animal and to avoid adverse effects.  
 
Bioavailability (F) is a term that quantifies the proportion (often measured in %) 
of a drug, which is absorbed and available to produce systemic effects (Toutain & 
Bousquet-Mélou,  2004a).  F  is  defined  by  the  European  Medicines  Evaluation 
Agency (EMEA, human guidelines) as follows: ‘bioavailability means the rate and 
extent  to  which  the  active  substance  or  active  moiety  is  absorbed  from  a 
pharmaceutical form, and becomes available at the site of action’ (Anon 2001). 
Since  it  often  is  difficult  to  collect  samples  from  the  target  tissue  blood  or 
plasma/serum is often used as a substitute for the site of action.  
 
There are several processes that may influence the oral bioavailability. Before 
the drug is absorbed across the apical cell membrane of the enterocytes the drug 
must be dissolved. The absorption can be limited by several processes in the lumen 
of the intestines and at the apical membrane of the enterocytes. Some conditions 
originate  in  physiochemical  factors  of  the  drug  itself,  such  as  the  lipophilicity, 
solubility,  size,  conformation,  ionisation  and  stability.  Other  processes  are 
depending on pharmaceutical factors such as dosage, crystal form and dissolution 
rate of the drugs. Also physiological, biochemical and pathological factors in the 
walls of the intestines may affect the absorption. In addition co-administration of 
other drugs, ingestion of xenobiotics and presence of food in the intestinal lumen 
will have impact on the absorption of the drug. The absorbed drug is then facing 
the enzymatic capacity of the enterocytes. The fraction that escapes metabolism in 
the  intestines  may  then  undergo  metabolism  in  the  liver  before  reaching  the 
systemic circulation. The events in the liver are dependent of the blood flow, the 
protein  binding,  and  the  influence  of  metabolising  enzymes  and  presence  of 
transport proteins in the hepatocytes.  
 
Other important PK parameters which often are assessed to estimate the fate of 
the drug in the body and to estimate correct dosage regimen are clearance (Cl), the 
volumes of distribution (Vd) and the half-life (t½) in the therapeutic interval. Cl  
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measures the overall ability of the body to eliminate a drug by scaling the drug 
elimination  rate  (amount  per  time)  by  the  corresponding  plasma  concentration 
level. This is an important PK parameter being one determinant of the dosage rate. 
Cl  multiplied  by  the  therapeutic  plasma  concentration  in  steady-state  (ss) 
conditions divided with the systemic bioavailability gives the correct dosing rate 
(Toutain & Bousquet-Mélou, 2004b). Terminal t½ is the time required to divide the 
plasma concentration by two after reaching pseudo-equilibrium (Fig. 1). The main 
clinical application of t½ is to select an appropriate length for the dosing intervals 
to maintain the therapeutic plasma concentration and avoid drug accumulation and 
delay in the time to reach ss conditions. T½ is a hybrid parameter depending on 
several physiological factors and is linked both to the total body Cl and Vd as well 
to the drug absorption rate in case of flip-flop phenomena, where the absorption 
rate  constant  is  lower  than  the  elimination  rate  constant  (Toutain  &  Bousquet-
Mélou, 2004c). Vd is the proportionality constant between total amount of drug in 
the body and plasma concentration. Plasma concentrations may be measured at 
different conditions e.g. at equilibrium or pseudo-equilibrium and therefore several 
Vd have been defined. Varea is the appropriate Vd to consider during the terminal 
phase of a pseudo-equilibrium, whereas Vss is the appropriate Vd to consider under 
ss conditions. A drug with large Vd can be selected in drug development to obtain a 
long terminal t½ even for drugs having a relatively high Cl (Toutain & Bousquet-
Mélou, 2004d).  
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Figure  1.  The  difference  between  a  pseudo-equilibrium  state  of  distribution  and  an 
equilibrium condition. Varea is the appropriate Vd to consider during the terminal phase of a 
pseudo-equilibrium,  whereas  Vss  is  the  appropriate  Vd  to  consider  under  steady-state 
conditions. Adopted from Toutain & Bosquet-Mélou 2004d. 
 
Variability  in  therapeutic  response  and  toxicity  to  drugs  can  be  related  to 
variation  in  PK  and/or  pharmacodynamics  (PD).  There  may  be  considerable 
variations between species, and also between and within breeds. Other factors of 
impact are age, gender, and body weight. Physiological factors such as blood flow 
to  various  organs  and  body  fat  content  may  also  affect  drug  distribution  and 
elimination. For animals in which group dosing or pour-on products are used the 
administered dose is not precise, which may lead to variable clinical response. Also 
the  owners’  compliance  with  the  prescribed  dosage  may  play  a  role.  Poor 
compliance may lead to inadequate responses and/or risk for toxicity. Anatomical 
and physiological differences in the intestines, liver and kidney may influence this 
variability. 
 
Vss 
Varea  
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Anatomy and physiology of the equine intestines, liver and 
kidney 
Being a herbivore the horse (Equus caballus) is highly specialised for a plant diet 
(Fig.  2).  This  has  entailed  a  specialised  dentition,  since  plant  food  must  be 
thoroughly  ground  before  the  digestive  enzymes  can  act  upon  it.  The 
gastrointestinal  tract of the horse is well adapted for its dual purpose of being 
important  for  the  digestion  and  absorption  of  nutrients  and  also  playing  an 
important  role  as  barrier  against  pathogens,  toxins  and  xenobiotics.  In  a  horse 
weighing about 500 kg the stomach has a volume varying from 8-15 litres and is 
remarkable small in size in relation to the animal and to the volumes consumed. 
The small intestine connects the stomach with the large intestine. It begins at the 
pylorus and terminates at the caecum. Its average length is about 22 metres, the 
average diameter is about 6-7 cm and the volume is about 40-50 litres. Its anterior 
part is the duodenum, which is followed by the mesenteric part, divided in jejunum 
and ileum. Both the duodenum and the ileum are is about 1 m in length. The large 
intestine extends from the termination of the ileum to the anus and is about 7.5-8 m 
in  length.  It  is  divided  in  caecum,  large  colon,  small  colon  and,  rectum.  The 
caecum  is  a  large  cul-de-sac  between  the  small  intestine  and  colon  and  has  a 
capacity  of  25-30  L.  The  ileocaecal  sphincter  controls  the  release  of  intestinal 
contents to the caecum and prevents colonic material to travel back into the small 
intestine. The large colon is 3-4 m in length and the diameter is 20-25 cm. Its 
capacity is more than double compared to caecum. The small colon begins at the 
termination of the great colon and is continued by the rectum. It is approximately 
3.5 m in length its diameter is 7.5-10 cm. The epithelium of the small intestines is 
composed mostly of absorptive cells - the enterocytes- that occur in different stages 
of maturity. The epithelium of the large intestine has many similarities with that of 
the small intestine; the most obvious difference being that the epithelium in the 
colon lacks the folding and villi structure and that there is also a higher amount of 
mucus producing cells than in the small intestine. The intraluminal pH is crucial for 
the fate of many drugs. The pH is usually below 6 in the duodenum and then 
increases to about 7.5 in the jejunum (Merritt, 1999). It is important to know pKa 
values of drugs since this determines if they are present in an anionic, cationic or 
zwitterionic state. Also the transport velocity, or effective permeability, over cell 
membranes is important for the overall extent of drug absorption over the intestinal 
wall (Lennernäs, 1998; Davis et al., 2006). 
 
 
Figure 2. Schematic view of the abdominal 
tract of the horse.  
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The liver, which is the major metabolising organ in the body, has a dual blood 
supply, comprising the hepatic artery, which oxygenates the organ from the aorta, 
and the portal vein, which carries blood from the intestine. The blood vessels 
divide into smaller branches, which end in sinusoids. The sinusoids run between 
the cords of hepatocytes and give rise to a central vein. The functional units of the 
liver are the hexagonal lobuli termed acini. The blood in the hepatic sinusoids and 
the bile in the bile-canaliculi flow in opposite directions to each other. The bile-
canaliculi are gathered to bile ducts, which are drained into the common bile duct. 
Horses have no gallbladder but a duct system which is highly developed, with a 
wide calibre of the bile ducts compensating for this. The bile is secreted in the 
duodenum. Compounds can be secreted into the intestine via the bile and then be 
reabsorbed (entero-hepatic cycling). 
 
The kidneys, which remove xenobiotics and metabolic waste products from the 
blood, weigh about 700 g each. The left one has a conventional form but the right 
one is shaped more like a heart or spade of a playing card. The kidneys consist of 
an outer cortex and an inner medulla. The functional units called pyramids have 
nephrons  and  collecting  ducts  which  empty  the  urine  into  the  renal pelvis.  In 
horses the kidneys are of a modified unipyramidal type, which implies that the 
pyramids  are  completely  fused  (the  boundaries  are  revealed  only  by  the 
arrangement  of  the  interlobar  arteries).  In  foals  there  is  a  clearer  indication  of 
lobation. The horse kidney contains 1-2 million urine-producing units (nephrons). 
Each nephron consists of a capillary network, glomerulus, and a tubular system 
lined with a continuous layer of epithelial cells and a basal lamina. The glomerular 
capillaries  are  surrounded  by  Bowman’s  capsule  and  the  tubule  distal  to  the 
capsule  is  divided  in  the  proximal  tubule,  loop  of  Henle,  distal  tubule  and 
collecting duct. The basic renal processes, i.e. glomerular filtration and tubular 
reabsorption and secretion, are similar to other mammals.  
 
Metabolising enzymes 
The biotransformation of drugs and other xenobiotics can be divided in two phases. 
Phase I, is the initial stage, usually catalysed by cytochrome P450 (CYP) enzymes, 
and phase II, the conjugation stage catalysed by a second class of enzymes. In 
phase I a functional group is introduced or uncovered in the molecule through 
oxidation,  reduction  or  hydrolysis  (Timbrell,  2000;  Guengerich,  2001;  Nebbia, 
2001; Isin & Guengerich, 2007). The altered molecule may then be conjugated to 
endogenous molecules in the phase II-reaction. The resulting conjugates are water-
soluble and hence easily excreted via urine or bile. However, biotransformation of 
drugs and other foreign compounds may sometime lead to formation of reactive 
intermediates, which can react with proteins and DNA and thereby cause harmful 
effects (Klassen, 2001). The liver plays a major role in drug metabolism because of 
its large blood supply and its extensive biotransformation capacity. In addition, 
drug-metabolising enzymes are present in extrahepatic tissues, such as the kidney, 
the nasal olfactory mucosa and the mucosal linings of the respiratory pathways and 
the  gastrointestinal  tract.  The  enzymes  in  the  intestinal  mucosa  are  probably 
important contributors to first pass metabolism at the intestinal absorption of orally 
administered drugs (Lin & Lu, 2001; Isin & Guengerich, 2007).   
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CYP enzymes  
The  cytochrome  P450-enzymes  (CYP-enzymes)  are  among  the  most  important 
enzymes involved in the metabolism of drugs and other xenobiotics through the 
initial  metabolism.  CYP-enzymes  are  a  group  of  heme-containing  membrane-
bound proteins present in the endoplasmic reticulum of the cells (Lin & Lu, 2001). 
To be enzymically active they require electrons. The first electron comes from 
NADPH via the assessory flavoprotein NADPH P450 reductase, a second electron 
may come from  NADH P450 reductase or, in some cases, from cytochrome b5 
(Sheweita,  2000;  Guengerich,  2001;  Vleet  et  al.,  2002).  CYP  constitutes  a 
multigene family, which consist of 27 gene families. At least 17 of these have been 
identified in mammals. The gene families are named with Arabic numbers (Voice 
et  al.,  1999).  They are divided into subfamilies and further into single distinct 
isoenzymes, such as CYP1A1 and CYP3A4. The subfamilies are designated by 
capital letters and the individual genes within the subfamily by Arabic numerals 
(Voice  et  al.,  1999;  Guengerich,  2001).  The  mammalian  CYP  families  can  be 
functionally subdivided into two major classes: those involved the biosynthesis of 
endogenous  molecules  such  as  steroids,  fatty  acids  and  bile  acid,  and  those 
involved in metabolism of xenobiotics (Lin & Lu, 2001). The three main CYP gene 
families,  responsible  for  most  of  the  xenobiotic  biotransformation  are  CYP1, 
CYP2 and CYP3 (Timbrell, 2000). In CYP1 and CYP3 there is only one subfamily 
(A),  whereas  in  CYP2  there  are  five  subfamilies  (A-E)  (Voice  et  al.,  1999). 
CYP3A4 is the predominant isoform of CYP3A. This isoenzyme is involved in the 
biotransformation  of  many  potentially  harmful  chemicals  and  commonly  used 
drugs. Thus, CYP3A4 metabolises an array of structurally different xenobiotics 
(Klaassen, 2001). The levels of CYP3A4 may vary and the catalytic activity of this 
enzyme  is  important  for  the  bioavailability  of  many  drugs  (Schwenk,  1988; 
Guengerich, 2001). Induction or inhibition of CYP3A4 appears to explain several 
well-known  drug  interactions  (Guengerich.  1999).  In  cases  where  the 
biotransformation  leads  to  metabolic  activation,  the  reactive  intermediates  are 
unstable and therefore unlikely to be transported from one tissue to another or even 
from one cell to another. Thus, tissue-specific toxicity is usually related to local 
bioactivation in the sensitive tissues.  
 
CYP enzymes have been extensively studied in humans and laboratory animals, 
whereas  relatively  little  is  known  about  these  enzymes in domestic animals. In 
particular  there  are  few  reports  on  the  presence  and  catalytic  activity  of  these 
enzymes in extrahepatic tissues of domestic animals. There are only a few reports 
in the literature dealing with equine hepatic or extrahepatic CYP-enzymes (Nebbia, 
2003, Larsson et al., 2003). Since many toxic substances have their targets in the 
extrahepatic tissues studies on tissue-specific metabolism have a significant impact 
on the understanding of tissue-specific toxic effects. The extrahepatic tissues are 
usually  morphologically  heterogenous  and  the  metabolising  capacity  may  be 
confined to specific cells in the tissues. This can be exemplified by the localisation 
of  CYP3A4  in  the  horse  nasal  olfactory  mucosa  which  has  been  shown  to  be 
confined to the sustentacular cells in the surface epithelium and to cells of the 
Bowman’s glands in the submucosa (Larsson et al., 2003). It is known that there  
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sometimes  are  large  species  difference  in  biotransformation  of  drugs  and other 
xenobiotics.  There  is  a  need  of  further  studies  aiming  to  characterise  the 
expression,  activity  and  localisation  of  the  CYP  enzymes  in  domestic  animals, 
including horses.  
 
Membrane transport 
Drugs can pass cellular membranes by passive transcellular diffusion, paracellular 
transport,  endocytosis  or  carrier-mediated  transport.  In  the  intestinal  mucosa 
passive diffusion is the most common route by which drugs passes the enterocytes. 
This  process  is  driven  by  the  concentration  gradient,  which  implies  that  the 
compound moves towards regions of lower concentration (or by an electrochemical 
gradient). The paracellular transport is mainly considered to be a passive process 
and is probably of minor importance for drugs since it is mainly small compounds 
that are transported this way. Endocytosis is a specialised form of transport where 
particles  are  internalised  by  invagination  of  the  apical  cell-membrane  into 
intracellular  vesicles.  There  are  several  carrier-mediated  transport  mechanisms. 
When the compounds are transported across the membrane in the direction of the 
concentration gradient, although the transport has a saturable behaviour, it is called 
facilitated diffusion. Transporters that utilise ATP to maintain a gradient across the 
membrane are called primary active transporters. Secondary active transporters use 
energy from ion gradients (often Na
+, Ca
+ and H
+ gradients) generated by primary 
active  transporters.  The  phase  II  conjugates  often  have  poor  membrane 
permeability. Hence carrier-mediated transport is necessary for biliary excretion 
and  secretion  from  hepatocytes  into  sinusoidal  blood,  and  in  addition  for  the 
excretion of drug metabolites from tubular cells of the kidney into the urine. 
 
P-gp 
It has been shown that many drugs are effluxed by P-glycoprotein (P-gp). P-gp is a 
membrane protein that belongs to the ATP-binding cassette super family. These 
transporters  are  designated  ABC-transporters.  The  main  function  of  these 
transporters  is  the  active  efflux  of  various  structurally  unrelated  exogenous 
compounds (coupled to ATP hydrolysis). The gene encoding for P-gp is termed 
multidrug  resistance  gene  1  (MDR1).  The  MDR  transporter  family  may  be 
overexpressed  in  cancers  in  response  to  chemotherapy  and  severely  restrict 
antitumour  drug  efficacy.  P-gp  exerts  a  protective  function  against  xenobiotic 
toxicity but, by limiting drug bioavalability, it may also reduce drug efficacy. It has 
been shown that many drugs that are metabolised by CYP3A are also effluxed by 
P-gp. P-gp is also important for the renal elimination of many drugs. In addition, 
due to its broad substrate specificity, P-gp may play a clinically relevant role in 
drug-drug (or drug-food) interactions (Loo & Clarke, 2005; Ambudkar, Kim & 
Sauna,  2006).  Recent  studies  at  our  department  have  shown  gene  and  protein 
expression of P-gp in enterocytes, hepatocytes and renal proximal tubular cells in 
horse (Tydén et al., 2006).  
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OATP  
The organic anion transport polypeptides (OATP) are involved in the transport of a 
wide range of anionic, cationic and zwitterionic compounds mainly with a high 
molecular weight (Hagenbuch & Meier, 2003). It has been suggested that OATPs 
have the capacity of bidirectional transport and that they may be driven by an anion 
exchange or to coupling of the cellular uptake of organic compounds (Shi et al., 
1995; Satlin, Amin & Wolkoff. 1997; Li, Meijer & Ballatori 2000). It has been 
suggested that inhibition of OATP1A2 and/or OATP2B1 in the intestine by some 
fruit  juices  may  explain  the  lowered  systemic  exposure  of  the  antihistamine 
fexofenadine in man (Dresser et al., 2002; Dresser, Kim & Bailey, 2005; Satoh et 
al., 2005). There are as yet no reports in the literature on the occurrence of OATP 
in horse tissues. 
 
Adverse drug reactions 
In horses, as in other species, adverse reactions can occur following treatments 
with various drugs. Adverse reactions to drugs can be of several different kinds, 
both caused by immune and non-immune mechanisms. Many of the adverse drug 
reactions are caused by predictable, non-immunologic mechanisms. This includes 
known  side-effects  related  to  treatments  of  certain  drugs.  Idiosyncratic  or 
intolerance reactions are often unpredictable, non-immune drug reactions leading 
to  overdose  effects  at  therapeutic  doses.  Idiosyncratic  reactions  are  defined  as 
genetic predispositions for some drugs that occur only in a (often) small percent of 
the  population.  Drug  intolerance  is  defined  as  a  lower  threshold to the normal 
pharmacological action of a drug. There are also unpredictable effects that may or 
may not be immune mediated. The immune mediated effects can involve different 
types  of  hypersensitivity:  Type  I  reactions  (IgE-mediated);  Type  II  reactions 
(cytotoxic); Type III reactions (immune complex); and Type IV reactions (delayed, 
cell-mediated). The most common drug-related hypersensitivity is Type I allergic 
reaction.  This  condition  includes  cross-binding  of  antigenic  drug-  or  drug-
metabolite-molecules to specific IgE-antibodies attached to mast cells. This results 
in release of histamine and other immunological mediators, which cause various 
manifestations of hypersensitivity, such as urticaria, angioedema and anaphylaxis. 
Important  drug-related  risk  factors  for  drug  hypersensitivity  are  related  to  the 
chemical properties and molecular weight of the drug. Drugs of high molecular 
weight and high structural complexity are more likely to be immunogenic than 
drugs  with  small  molecular  weight.  Another  factor  of  importance  for 
hypersensitivity drug reactions is the route of drug administration; subcutaneous 
(s.c.),  i.m.  and  i.v.  administrations  are  more  likely  to  cause  hypersensitivity 
reactions  compared  to  oral  administration.  This  could  be  explained  by  the 
effectiveness of antigen presentation in the skin, the adjuvant effects of depot drug 
preparations after i.m. administrations, and the high concentrations of circulating 
drug antigen rapidly achieved at i.v. therapy.  
 
In  horses,  there  are  several reports of different kinds of adverse reactions to 
different  kind  of  drugs  (Tjälve,  1997;  Woodward  2005).  Vaccines  may  cause  
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injection site reactions, with stiffness, fever and depression (Tjälve, 1997). For 
anaesthetics,  sedatives  and  analgesics,  negative  effects  can  be  urticaria,  local 
reaction on the site of injection or excitation (Tjälve, 1997). Non-steroidal anti-
inflammatory  drugs  (NSAID),  such  as  phenylbutazone,  can  cause  gastric  and 
intestinal  ulceration,  sometimes  leading  to  peritonitis  and  death  (Brumbaugh, 
2001).  
 
Adverse effects to antimicrobial drugs are reported relatively frequently in horses 
(Gray et al., 2003; Dyer et al., 2005). Thus, both oral and i.v. treatments with 
trimethoprim-sulfonamides have been associated with collapse and death (Tjälve, 
1997). Fatal diarrhoea has been reported in association with antibiotics especially 
erythromycin  but  also  trimethoprim  and  sulfonamides  (Wilson  et  al.,  1996; 
Båverud et al., 1998; Stratton-Phelps, Wilson & Gardner 2000). 
 
Penicillin has a wide safety margin and is usually well tolerated. Yet adverse 
reactions  other  than  gastrointestinal  disturbances  are  observed  (Marshall,  1980; 
Allpress & Heathcote, 1986; Nielsen et al., 1988; Tjälve, 1997). Thus, it is well 
known that acute adverse reactions may occur following i.v. or i.m. injections of 
benzylpenicillin in horse. Penicillin, or its metabolites, have an affinity for proteins 
and may form hapten conjugates, which participate in immunological reactions. 
However,  hypersensitivity  reactions  to  penicillin  have  been  reported  to  be 
relatively rare in animals, although the number and occurrence are not known in 
detail  (Wilcke,  1986;  Davis,  1987).  Benzylpenicillin  is  used  as  highly  water-
soluble sodium or potassium salts or as a procaine salt with low water-solubility. 
The sodium and potassium salts are usually injected i.v., whereas the procaine salt 
is used as an i.m. depot preparation. The latter must be dissolved into free procaine 
and  benzylpenicillin  before  absorption  to  the  blood,  implying  that  therapeutic 
benzylpenicillin-concentrations will be maintained for at least 24 hours (Uboh et 
al., 2000). As regards procaine benzylpenicillin release of a high concentration of 
free procaine in the circulation may lead to systemic toxicity. The risk factors for 
the adverse reactions to benzylpenicillin in horses are discussed in this thesis.  
 
Drug interactions 
When two or more drugs are administered over an overlapping time period, there is 
a possibility of drug interactions. Drug interactions are important causes of drug 
related toxicity (Kaufman & Shapiro, 2000). A drug interaction may be defined as 
occurring when the pharmacological or clinical response to a combination of drugs 
is different from that anticipated from the known effects of the single drugs. The 
net effect may be synergism, antagonism, alteration of the effect of one or more of 
the drugs, or idiosyncratic effects. A number of drugs may interact simultaneously 
at  different  sites,  so  it  can  be  difficult  to  attribute  an  interaction  to  a  single 
mechanism (Ito, Brown & Houston, 2004). There are several plausible mechanisms 
underlying  drug  interactions.  A  drug  with  a  high  affinity  for  a  receptor  may 
displace another drug with lower affinity from the receptor. Also alteration in the 
levels  of  transport  proteins  can  affect  the  plasma  concentrations  of  drugs. 
Inhibition or induction of the enzymes involved in the metabolism of drugs may 
occur. Inhibited drug metabolism may result in undesirable elevations in plasma  
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concentrations of drugs or metabolites, which in turn can lead to serious adverse 
effects (Kolars et al., 1993). Enzyme induction may increase the drug’s metabolism 
and  elimination  rate  and  deteriorate  its  pharmacological  effect  as  a  result  of 
decreases in plasma concentrations. It has been proposed that P-gp and CYP3A are 
functionally linked and may act in concert to limit the passage of drugs across the 
enterocytes (Benet & Cummins, 2001). Herbs or herbal remedies and fruit juices 
may also affect the levels and activities of P-gp and CYP3A. In this thesis the 
interaction of ivermectin, which is a known substrate and inhibitor of P-gp, on the 
pharmacokinetics of the two antihistamines fexofenadine and cetirizine has been 
examined.  
 
Tools for studying the fate and effect of drugs in horses 
There are different ways to study the fate of drugs in the horse. In this thesis both 
in vitro and in vivo methods were used. 
 
CYP3A studies 
The mRNA expression, immunohistochemical localisation and catalytic activity of 
CYP3A in the intestines of horses were examined using an array of different in 
vitro  techniques.  For  detection  of  CYP3A-mRNA  in  the  intestines  a  real-time 
reversed  transcription  polymerase  chain  reaction  (RT-PCR)  was  used. 
Immunohistochemistry was used to trace the cellular localisation of CYP3A. The 
activity  of  CYP3A  in  microsomal  fractions  was  determined  with  the  CYP3A 
selective  probe  DFB  (3-(3,4-difluorobenzyloxy)-5,5-dimethyl-4-(4-
methylsulfonylphenyl)-5H-furan-2-one).  DFB  is  metabolised  to  the  fluorescent 
metabolite DFH (3-hydroxy-5,5-dimethyl-4-(4-methylsulfonylphenyl)-5H-furan-2-
one; Fig. 3).  
 
 
  
21 
0
20
40
60
80
100
120
140
160
0 5 10 15
Time
C
o
n
c
e
n
t
r
a
t
i
o
n
 
o
r
 
e
f
f
e
c
t
Conc C(t)
Effect E(t)
Figure  3.  The  formation  to  the  fluorescent  metabolite  3-hydroxy-5,5-dimethyl-4-(4-
methylsulfonylphenyl)-5H-furan-2-one  (DFH)  from  3-(3,4-difluorobenzyloxy)-5,5-
dimethyl-4-(4-methylsulfonylphenyl)-5H-furan-2-one (DFB) by CYP3A-enzymes. 
Pharmacokinetic, pharmacodynamic and interaction studies 
Horses were used in clinical in vivo trials to study two different antihistamines by 
blood sampling and PK analyses. The PD, measured as the antihistaminic effect 
was assessed by intradermal histamine injections and then measurements of the 
reactions. Interaction studies were performed by examination of effect on the PK of 
the  antihistamines  after  pre-treatment  with  ivermectin,  which  like  the 
antihistamines, is a substrate for P-gp. 
 
PK deals with the time course of drugs in the body. Specifically it is the study of 
drug  absorption,  distribution  and  elimination.  Parameters  describing  this  are 
calculated  by  mathematical  models  and  include  F,  area  under  the  plasma 
concentration  time  curve  (AUC),  Cl,  Vd,  and  t½.  There  are  several  models 
available,  such  as  compartmental  or  non-compartmental  models,  and  there  are 
guidelines for best fit using model selection, weighing schemes, residual analyses 
and other diagnostic tools. 
 
PD  may  be  defined  as  a  study  of  actions  of  drugs  on  the  body  or  on 
microorganisms or parasites within or on the body. The PD of any given drug can 
be  studied  at  many  different  biophase  levels  from  sub-molecular,  molecular, 
cellular,  tissue/organ  system  to  whole  body  (i.e.  at  an  organism  level).  It  is 
essential that a relevant endpoint has been chosen to measure the drug action. The 
PD  model  relates  the  biophase  concentration  to the effect (Holford & Sheiner, 
1981; Lees, Cunningham & Elliott, 2004). 
 
PKs  and  PDs  attempt  to  relate  the  interaction  of  a  drug  to  a  biological 
environment. There are models that aim at linking PK and PD. Generally PK/PD 
modelling requires three separate models: one model for PK data, one for PD data 
and a link model describing the passage of drugs from plasma to the biophase 
(Toutain et al.1994; Toutain & Lees, 2004). Often the effect lags some time behind 
plasma concentration. Hence, concentration cannot be incorporated directly into a 
PD model. This can be illustrated by plotting the effect (Y-axis) versus the plasma 
concentration (X-axis) and follow the data points in chronological order; this will 
result in a hysteris loop, which is a Greek word meaning coming late (Fig 4). The 
link model is used to deal with this problem. 
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Figure 4. Plasma concentration-time and effect-time relationships are not in phase (left). 
The  peak  concentration occurs earlier than the peak effect. An arithmetic plot of effect 
versus concentration reveals a hysteris loop (right). 
Esterase activity studies  
An in vitro experiment was used to assess the activity of plasma esterases in horses 
reacting adversely to procaine benzylpenicillin and in control horses. Following 
entry into the systemic circulation procaine is hydrolyzed by plasma esterases to 
the  non-toxic  metabolites  para-aminobenzoic  acid  (PABA)  and 
diethylaminoethanol  (Fig.  5;  Tobin  et  al.,  1976).  To  examine  plasma  esterase 
activity samples of horse plasma were incubated with procaine in a water-bath and 
the  formation  of  PABA  was  then  analysed  by  high-performance  liquid 
chromatography (HPLC). 
 
 
 
Figure  5.  Hydrolysis  of  procaine  to  para-aminobenzoic  acid  (PABA)  and 
diethylaminoethanol by plasma esterases. 
 
Examined drugs 
 
Antihistamines  
There is a need for an antihistamine (histamine H1-receptor antagonist) with good 
bioavailability for oral therapy of allergic disorders in horse. In Sweden no such 
drug is approved for use in animals. However, antihistamines are tentatively used 
in  veterinary  medicine  to  treat  hypersensitivity  conditions  related  to  effects  of 
histamine. In hypersensitivity reactions, allergens cross-bind IgE on the surface of 
mast cells and basophils, thereby causing degranulation. Histamine is one of the 
inflammatory  mediators  released  together  with  proteolytic  enzymes, 
prostaglandins,  leukotrienes  and  proinflammatory  cytokines.  The  free  histamine 
contributes  to  the  different  clinical  signs  of  allergy,  such  as  oedema,  urticaria, 
eczema,  discharges  from  mucous  membranes  and  eyes  and  circulatory  shock  
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syndromes (Adams, 1995). Antihistamines act as competitive antagonists for the 
histamine receptors in the tissues. In equine therapy histamine H1-antagonists such 
as  tripelennamine,  promethazine  and  chlorpheniramine  have  been  used  in  the 
treatment  of  hypersensitivity  to  biting  insects  of  the  Culicoides  spp.  (Morrow, 
Quinn  &  Baker,  1986;  Rosenkrantz,  1995;  Foster,  McKelvie  &  Cunningham, 
1998). Histamine H1-antagonists may also be used in other conditions in which 
histamine can be a critical mediator, such as allergic reactions to venoms and other 
antigens and drug induced anaphylactic shock (Adams, 1995). The antihistamines 
examined in this thesis are fexofenadine and cetirizine. 
 
Fexofenadine 
Fexofenadine  (Fig.  6),  a  metabolite  of  terfenadine,  is  a  selective  non-sedating 
histamine H1- receptor antagonist that in man is clinically active in the treatment of 
seasonal allergic rhinitis and chronic idiopathic urticaria (Simpson & Jarvis, 2000). 
Fexofenadine has very little or no anti-cholinergic activity (Orzechowski, Currie & 
Valancius, 2005; Liu & Farley, 2005). In man fexofenadine is regarded as being 
safe, even at high plasma concentrations (Russell, Stoltz & Weir, 1998; Simpson & 
Jarvis 2000). Fexofenadine is metabolised only to a minor degree in man and rat 
(Lippert et al.,1995; Kamath et al., 2005). Fexofenadine is a zwitterion, with one 
carboxyl  and  one  piperidine  group,  having  pKa  values  of  4.25  and  9.53 
respectively (Yasui-Furukori et al., 2005). 
 
Cetirizine  
Cetirizine  (Fig.  7),  a  metabolite  of  hydroxyzine,  is  a  non-sedative  second 
generation H1 antihistamine widely prescribed and with demonstrated efficacy in 
the  treatment  of  urticaria  and  pruritus  in  humans  (Simons,  2001;  Zuberbier  & 
Henz, 1999). In man cetirizine has pharmacodynamically and pharmacokinetically 
favourable  characteristics  such  as  rapid  onset  of  action  and  a  low  degree  of 
metabolism. It is well tolerated, safe and has been shown not to alter memory, 
attention, alertness or performance in humans (Pagliara et al., 1998; Benedetti et 
al.,  2001,  Curran,  Scott  &  Perry,  2004,  Theunissen  et  al.,  2004;  Theunissen, 
Vermeeren  &  Ramaekers,  2006).  Cetirizine  also  displays  high  affinity  and 
selectivity for cloned human H1-histamine receptors (Gillard et al., 2002). At a pH 
between 3.5 and 7.5 cetirizine exists nearly exclusively as a zwitterion, and also 
appears to form partial intramolecular charge neutralisation in folded conformers 
of lower polarity (Pagliara et al., 1998). 
  
24 
 
 
Figure 6. Stereo view of fexofenadine. 
 
 
 
Figure 7. Stereo view of cetirizine. 
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Figure 8. Proposed stereo view of ivermectin. 
 
Ivermectin 
Ivermectin  (Fig.  8) is a macrocyclic lactone. This constitutes a large family of 
structurally related compounds widely used for the treatment of both internal and 
external  parasites  (McKellar  &  Benchaoui,  1996).  Ivermectin  is  a  well-known 
substrate of P-gp (Schinkel et al., 1994) and has also been shown to be a P-gp 
inhibitor (Didier & Loor, 1996). Ivermectin is used in this thesis for interaction 
studies with fexofenadine and cetirizine. 
 
Benzylpenicillin 
Benzylpenicillin (Fig. 9) is the most frequently used penicillin-derivative in equine 
therapy.  It  is  used  as  highly  water-soluble  sodium  or  potassium  salts  or  as  a 
procaine salt with low water-solubility. The sodium and potassium salts are usually 
injected i.v, whereas the procaine salt is used as an i.m. depot preparation. The 
latter must be dissolved into free procaine and benzylpenicillin before absorption 
to  the  blood,  implying  that  therapeutic  benzylpenicillin-concentrations  will  be 
maintained for at least 24 hours (Uboh et al., 2000). Penicillin, or its metabolites, 
have an affinity for proteins and may form hapten conjugates, which participate in 
immunological reactions. (Downham et al., 1978). In this thesis clinical signs and 
etiology of adverse reactions to procaine benzylpenicillin and sodium/potassium 
benzylpenicillin in horses are described. 
 
Procaine 
Procaine (Fig. 9) forms a salt together with benzylpenicillin. The procaine delays 
the absorption of benzylpenicillin from the i.m. injection site. In addition it acts as 
a  local  anaesthetic,  decreasing  the  discomfort  of  injecting  a  large  volume  of  
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benzylpenicillin  into  the  muscle  (Uboh  et  al.  2000).  Inadvertent  intravascular 
administration of the procaine benzylpenicillin may result in a rapid dissociation of 
the salt into procaine and benzylpenicillin when diluted in the large blood volume. 
Adverse reactions may then be induced due to an effect of free procaine on the 
CNS.  Following  entry  into  the  systemic  circulation  procaine  is  hydrolyzed  by 
plasma esterases to non-toxic metabolites (Tobin et al., 1976). Procaine toxicity 
may occur when the amount of free procaine in the blood exceeds the hydrolysing 
capacity of the plasma esterases. In this thesis procaine was used in an in vitro 
experiment  to  assess  if  the  horses  reacting  acutely  to  procaine  benzylpenicillin 
have lower plasma esterase activity compared to non-reacting control horses. 
 
 
 
 
Figure  9.  The  structure  of  the  procaine 
benzylpenicillin  salt.  The  benzylpenicillin  is 
shown above and the procaine below. Procaine 
benzylpenicillin  has  low  water  solubility.  If 
procaine  is  exchanged  by  sodium  (Na
+)  or 
potassium  (K
+)  the  more  water-soluble  Na/K 
benzylpenicillin salts are formed. 
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Aims 
The general aim of the present thesis was to increase the basic knowledge of some 
factors determining the fate and effect of some drugs in the horse.  
 
The specific aims of this thesis were: 
 
• to elucidate the regional distribution of gene expression and catalytic activity and 
the cellular localisation of CYP3A in the intestines in horses. 
 
•  to  study  the  pharmacokinetics  and  the  antihistaminic  effect  of  the  two 
antihistamines fexofenadine and cetirizine in horses.  
 
• to examine if pre-treatment with ivermectin would affect the pharmacokinetics of 
fexofenadine and cetirizine in horses.  
 
•  to  increase  the  knowledge  of  the  etiology  of  the  adverse  reactions  to 
benzylpenicillin in horses.  
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Material and Methods 
Horses 
In paper I tissues from seven Standard bred trotters, 3-9 years old, were collected 
from a local abattoir. In paper II five mares, 6-12 years old, were used. Three of 
the horses were Standard bred trotters, one was a Swedish warm blood riding horse 
and one was a New Forest. In paper III seven healthy Standard bred trotters (five 
mares and two geldings), 5-21 years old, were used. In paper IV six Standard bred 
trotters (mares), 5-21 years old, were used. In paper V information on adverse 
reactions to benzylpenicillin in 59 horses of different breeds were collected. The 
horses ranged in age from 8 months to 29 years and comprised 34 mares and 25 
geldings.  Within  this  group  blood  samples  were  collected  from  31  horses  (16 
mares and 15 geldings aged 2-24 years). Seventeen horses of different breeds (8 
mares and 9 geldings aged 2-20 years) were used as controls. The control horses 
had  previously  been  treated with procaine benzylpenicillin without any adverse 
reactions. All study protocols were approved by the Animal Ethics Committee, 
Uppsala, Sweden. 
 
Real-time RT-PCR 
In paper I, total RNA from intestinal mucosa and liver was prepared and the purity 
and  the  approximal  concentration  were  determined  spectrophotometrically.  The 
samples were then run on an ethidium bromide agarose gel to check the integrity of 
the RNA. The primers were designed based on pig, rat and human CYP3A4 cDNA 
sequences.  A  gene-region  conserved  between  the  species  was  found.  The  pig 
cDNA was chosen as template. The sequences of the primers were 5´-CAG CCT 
GGT GCT CCT CTA TC-3´(forward) and 5´-TCA ACA CCC TTA CGG TAG 
CC-3´(reverse). The primers were assessed for functionality and specificity and 
then quantified by PCR reactions with an iCycler. At the time for this study the 
gene-sequence for equine CYP3A4 was unknown so we could not exclude that the 
primer-pair may generate PCR-products for other CYP3A isoenzymes. The RNA 
samples were pretreated with DNAse (Huang et al., 1996) and the exact RNA 
concentrations  were  measured  in  a  microplate  reader.  The  real-time  RT-PCR 
reaction was carried out using Rotor-Gene 3000. Quantification was done using 
Rotor-Gene software and a melt curve analysis was done to check the specificity of 
the obtained PCR-product. 
 
Immunohistochemistry 
In paper I, immunohistochemistry was used to trace the cellular localisation of 
CYP3A in the intestinal mucosa in various parts of the intestines and in the liver. 
Paraformaldehyde-fixed tissue pieces were dehydrated and embedded in paraffin. 
Five µm thick tissue sections were deparaffinised, hydrated and rinsed and then 
incubated with primary antibodies (rabbit anti-human) against CYP3A4. Secondary 
antibodies (goat anti-rabbit) were then applied to the sections, which thereafter 
were stained for visualisation of the CYP3A immunoreactivity.  
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CYP3A enzyme assay 
In paper I microsomes were prepared by homogenisation of the tissues from the 
intestinal mucosa and the liver followed by centrifugation twice at 10000 x g for 25 
min. The supernatants were then centrifuged at 105000 x g for 1 hour. The protein 
contents of the microsomes were determined in a microplate reader (Smith et al., 
1985). The activity of CYP3A in the microsomal fractions was determined with a 
96-well plate assay using the probe DFB. DFB is metabolised to the fluorescent 
metabolite DFH mainly by CYP3A4 and to a low extent also by CYP3A5 (Chauret 
et al., 1999). An inhibition assay was also conducted using the CYP3A inhibitor 
ketokonazole. 
 
Drug administration 
In  papers  II  and  III  the  i.v. administrations of antihistamines were given via a 
jugular vein catheter; the oral administrations were given via a nasogastric tube. 
Ivermectin, in a paste formulation for equine use, was given into the mouth. In 
paper IV the oral administrations were given mixed with sugar beet. 
 
Blood sampling  
In papers II and III the blood samples were collected via a jugular vein catheter 
into  test  tubes  with  heparin  as  anticoagulant.  In  paper  IV  blood  samples  were 
collected via a jugular vein catheter after the last administration and at other time 
points  via  direct  vein  puncture.  In  paper  V  blood  samples  were  taken  from  a 
jugular  vein  and  collected  into  heparin  vacutainer  tubes  and  placed  in  an  ice 
bucket.  All  samples  were  centrifuged  at  1500  g  at +4°C for 15 min to collect 
plasma. In paper II, III and IV plasma was stored at -20°C and in paper V at -70°C 
until analysis. 
 
Recording of the pharmacodynamic effect 
The antihistaminic effects of fexofenadine and cetirizine were recorded using an 
intradermal test (Fig. 10). The horses were shaved with an electric clipper on the 
lateral  neck  prior  to  intra-dermal  injections  with  7µg/site  of  histamine 
hydrochloride (0.1 mg/ml, ex tempore, Apoteket AB) using 27-gauge needles. The 
diameter of the skin reaction was measured after 20 min using a vernier calliper. 
Histamine-injections  before  administration  of  antihistamines  served  as  positive 
controls. Sterile saline (0.07 ml) served as negative controls. Histamine-injections 
were then performed at different time points. The diameters of each wheal were 
determined by taking the mean of two perpendicular diameters. The wheal areas 
were  then  calculated  and  the  antihistaminic  effect  was  expressed as percentage 
inhibition of wheal formation compared to controls. Thus, for each horse the effect 
of the antihistamine on wheal areas were calculated by comparing the effect of 
histamine before and after administration of the drug. 0% inhibition was defined as 
the  wheal  area  after  the  histamine  injection  alone  (before  administration  of 
antihistamine)  and  100%  inhibition  as  the  wheal  area  after  injection  of  sterile 
saline. In paper II one to three injections were performed at each occasion and the  
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mean  value  was  used  for  further  calculations.  The  negative  control  value  was 
calculated  from  at  least  5  administrations  for  each  horse.  In  paper  IV  three 
injections were performed at each occasion and the median value was used for 
further calculations. The negative control value was calculated from at least 11 
administrations for each horse.  
 
 
 
Figure  10.  Histamine-induced  cutaneous  wheal  formation  in  horse.  Photo:  Gunnar 
Carlsson. 
 
Analysis of antihistamines 
In  paper  II  the  plasma  concentrations  of  fexofenadine  quantiﬁed  by  liquid 
chromatography electrospray tandem mass spectrometry (LC-ESI-MS/MS) by use 
of a liquid chromatograph with a binary pump, a quadrupole-hexapole-quadrupole 
mass spectrometer with an electrospray interface and a Luna C8 chromatographic 
column.  In  papers  III  and  IV  the  plasma  concentrations  of  cetirizine  were 
quantified  by  LC-ESI-MS/MS  in  a  similar  way  as  mentioned  for fexofenadine. 
[
2H6]-fexofenadine (Toronto Research Chemicals Inc.) and [
2H4]-cetirizine (C/D/N 
Isoptopes) were used as internal standards. 
 
Analysis of PABA 
In paper V horse plasma was incubated with procaine (20 µg/ml of plasma) in a 
water bath at 37°C for 12 min and the amount of PABA formed was measured by 
HPLC.  Samples  were  then  taken  and  deproteinised  with  acetonitrile  and 
centrifuged  at  12000  g  for  15  min.  For  determination  of  PABA  20  µl  of  the 
supernatant were injected onto the HPLC. The endogenous PABA-levels in the 
plasma were determined separately and subtracted from the incubated samples.  
 
Pharmacokinetic analyses 
For each horse the plasma concentrations of cetirizine were plotted versus time and 
the  data  were  analysed  using  the  software  program  Win  Nonlin  2.0  or  5.0.1 
(Pharsight Corporation). Different models and weighting factors were assessed by 
visual inspection of the curve fits and the residuals’ scatter plots, and combined 
with  the  goodness  of  fit  measures  incorporated  in  the  software,  including  the 
Akaike  Information  Criterion  and  the  Schwartz  criteria.  These  are  statistical 
models that measure the trade off between the complexity of the model and how  
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well the model fits the data. They are used to decide the most suitable model when 
comparing the same data set and the same weighting scheme. The smallest Akaike 
and Schwartz values give the best fit for the models compared, whilst the most 
adequate weighing factor is measured by residual analysis.  
 
In paper II a non-compartmental model was used for all data to compare the 
treatment groups (i.v and oral administration of fexofenadine with versus without 
ivermectin  pre-treatment).  The  time  (Tmax)  to  obtain  the  maximal  plasma 
concentration (Cmax) and the Cmax were read from the plotted concentration-time 
curve of each individual animal. The area under the curve (AUC) was calculated 
using the linear trapezoidal approximation. To extrapolate the AUC from time zero 
to infinity, the terminal slope (λ) was used. Half-lives were determined from t½ = ln 
2/λ. The mean residence time (MRT) was calculated by the linear trapezoidal rule 
with extrapolation to infinity, using the formula: 
MRT = AUMC / AUC, 
where, AUMC is the area under the first moment curve. 
The oral bioavailability (F) was calculated from the AUC by using the equation: 
F (%) = 100 × (AUC oral ×dose iv) / (AUC iv ×dose oral) 
The PK equation best fitted to use to the PK/PD link was a three-compartment 
model:  
C (t) = I1(e
-k1t - e
-k1t*) + I2(e
-k2t - e
-k2t*) + I3(e
-k3t - e
-k3t*) 
where C is the plasma concentration at time t and t* (the length of infusion) is 
included to create a factor that compensates for the time delay in relation to an i.v. 
bolus model (Fig. 11). The pharmacokinetic factors were calculated from the y axis 
intercepts (I1-3) and the exponents of the respective phase (k1-3). The weighting 
factor of choice was 1/the predicted Y-values
2 with iterative reweighting so that the 
weight redefines for each observation.  
 
 
Figure  11.  The  three-compartment 
pharmacokinetic model with constant rate 
infusion.  K12  represents  the  rate  from 
compartment  1  to  compartment  2,  K21 
the  rate  from  compartment  2  to 
compartment  1,  K13  represents  the  rate 
from  compartment  1  to  compartment  3, 
K31  the  rate  from  compartment  3  to 
compartment  1,  K10  the  rate  of 
elimination. Model from the WinNonLin 
library.  
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In papers III and IV the data were analysed and best fitted to a two-compartment 
model with first-order input, first-order output using the equation:  
C (t) = A(e
-αt ) + B(e
-βt) +C(e
-K01t) 
where C is the plasma concentration at time t,  K01 is the absorption rate and α and 
β the declining rates (Fig. 12). The appropriate weighing factor was found to be 
1/Y,  were  Y  is  the  observed  concentration.  The  primary  pharmacokinetic 
parameters were calculated from the y axis intercepts (A-C) and the exponents of 
the respective phase (α, β and K01). Secondary parameters calculated were the 
AUC from time zero to infinity, the Tmax, Cmax and α and β half-lives. For paper III 
the mean residence time (MRT) was calculated by the linear trapezoidal rule with 
extrapolation to infinity, using the formula: MRT = AUMC / AUC. For paper IV 
the Tmax, Cmax for the second dose and the trough plasma concentration were read 
from the plotted concentration-time curve of each individual animal.  
 
 
 
Figure 12. The two-compartment pharmacokinetic model with first-order input, first-order 
out-put. K01 represents the rate of the absorption, K12 the rate from compartment 1 to 
compartment  2,  K21  the  rate  from  compartment  2  to  compartment  1,  K10  the  rate  of 
elimination. Model from the WinNonLin library. 
 
Pharmacokinetic/pharmacodynamic link model 
In papers II and IV a PK/PD link model was applied using pharmacodynamic data 
from a concentration/response equation and pharmacokinetic data from the three- 
respective two-compartmental models. Using the PK/PD link model, the maximal 
effect  (Emax),  the  plasma  concentration  producing  50  %  of  the  maximal  effect 
(EC50)  and  the  rate  constant  for  the  elimination  of  drug  from  the  effect 
compartment (Ke0) were calculated (Toutain et al., 1994, Toutain & Lees, 2004). 
The concentration/response equation used was: 
E = (Emax × C
γ
e) / (C
γ
e + EC
γ
50)  
where Ce is the apparent effect compartment concentration (Fig. 13). Gamma (γ) is 
the  slope  factor  which  has  its  origin  in  the  Hill  coefficient  and  expresses  the 
sigmoidicity of the concentration-effect relationship.  
 
 
 
 
Figure  13.  The  Sigmoid  Emax 
pharmacodynamic model describing 
the concentration and the response. 
Model from the WinNonLin library.  
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Statistical analysis 
In  paper  I  a  Pearson´s  product  moment  correlation  was  used.  In  paper  II  the 
pharmacokinetic data were subjected to statistical analyses using Student’s t-test 
(paired,  two-tailed  test).  For  pharmacodynamic  data  an  ANOVA  was  used 
followed  by  Dunnet´s  post-hoc  test,  comparing  wheal  areas  before  and  after 
treatment. The significance level was set at 0.95 (p < 0.05). For papers I and II, the 
software was Statview 4.0 (SAS Institute). In paper III pharmacokinetic data were 
subjected to statistical analyses using Student’s t-test (paired, two-tailed test). In 
paper IV an ANOVA was used followed by Dunnet´s post-hoc test, comparing 
wheal areas before and after treatment. The significance level was set at 0.95 (p < 
0.05). In paper V all plasma data were tested for normality with Anderson-Darling 
Normality Test before further analyses (p = 0.51). Plasma data were subjected to 
statistical analyses using Student’s t-test. The software was Minitab
®, release 14 
(Minitab Ltd.) for papers III, IV and V. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
De omnibus dubitandum est 
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Results and Discussion 
Occurrence and activity of CYP3A in the intestines (Paper I) 
Real time RT-PCR analyses showed that the highest CYP3A mRNA expression 
was  present  in  the  duodenum  with  decreasing  levels  towards  jejunum,  ileum, 
caecum, and colon. The expression in the liver was similar to that in the anterior 
part  of  the jejunum, but about 4.5 times lower than in the anterior part of the 
duodenum.  Immunohistochemistry  showed  CYP3A  immunoreactivity  in  the 
cytoplasm of the enterocytes, which decreased distally along the intestinal tract. 
Studies in man, dog, rat, trout and mice have shown a similar pattern of intestinal 
mRNA expression and immunostaining (Bonkovsky et al., 1985, Murray & Burke, 
1995; Cotreau et al., 2000; Kyokawa et al., 2001; Lee et al., 2001; Jin et al., 2006)  
CYP3A dependent metabolic activity rose slightly from the anterior to the distal 
part of the duodenum and the anterior part of the jejunum and then declined to the 
middle and distal parts of the jejunum and the ileum, caecum, and colon. Studies in 
man have shown a similar pattern with a slight increase from the duodenum to the 
middle jejunum and then a decline towards the ileum. It has also been shown that 
the NADPH cytochrome P450 reductase activity exhibits the same pattern (Paine 
et  al.,  1997).  This  may  explain  why  there  is  no  strict  correlation  between  the 
mRNA expression and the CYP3A metabolic activity as the activity of CYP is 
dependent  on  the  activity  of  NADPH  cytochrome  P450  reductase.  Our  results 
suggest that intestinal CYP3A in horses may limit the oral bioavailability of drugs 
and xenobiotics that are CYP3A substrates. CYP3A in the small intestine may play 
a  major  role  in  the  fist-pass  metabolism  and  therefore  affect  the  therapeutic 
efficacy of some drugs when administered orally in horses. 
 
Fate of the antihistamines and interactions with ivermectin 
(Paper II and III) 
The PK of the histamine H1-antagonists fexofenadine and cetirizine and the effects 
of pre-treatment with the antiparasitic macrocyclic lactone ivermectin on the PK of 
the  antihistamines  were  studied  in  horses.  After  intravenous  infusion  of 
fexofenadine at 0.7 mg/kg bw (paper II) the mean t½ was 2.4 h (range: 2.0-2.7 h), 
the apparent volume of distribution 0.8 L/kg (0.5-0.9 L/kg), and the total body 
clearance  0.8  L/h/kg  (0.6-1.2  L/h/kg).  The  t½  after  oral  administration  of 
fexofenadine  was  about  5.0  h,  whereas  the  t½  after  i.v.  administration  was 
considerably shorter. After oral administration the absorption rate can influence the 
rate  of  elimination  (flip-flop  phenomenon)  and  the  apparent  t½  may  therefore 
increase (Baggot, 1992). After oral administration of fexofenadine at 10 mg/kg bw 
bioavailability was 2.6% (1.9-2.9%). The oral bioavailability of fexofenadine in 
mouse is also about 2%. The F in man has not been determined in detail, but 
appears to be higher than in horse and mouse (Lippert et al.,1995; Krishna et al., 
2004;  Thahara  et  al.,  2005).  Oral  therapy  of  horses  with  fexofenadine  are  not 
suitable due to the low bioavailability. 
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Ivermectin  pre-treatment  (0.2  mg/kg  orally)  12  h  before  oral  fexofenadine 
decreased the bioavailability to 1.5% (1.4-2.1%). In addition the area under the 
plasma concentration time curve decreased by 27%. Ivermectin did not affect the 
pharmacokinetics  of  i.v.  administered  fexofenadine.  Ivermectin  may  therefore 
influence  fexofenadine-absorption  by  interfering  in  intestinal  efflux  and  influx 
pumps  such  as  P-gp  and  OATP.  Inhibition  of  the  P-gp  efflux  pump  would  be 
expected to result in an increased uptake of fexofenadine, thus the opposite to the 
observed  effect.  Since  several  P-gp-inhibitors  are  also  inhibitors  of  OATPs 
(Cvetkovic et al., 1999) an alternative mechanism would be an ivermectin related 
inhibition of OATP-dependent influx pumps.  
 
After oral administration of cetirizine at 0.2 mg/kg bw (paper III) the mean t½ 
was 3.4 h (range: 2.9-3.7 h) and the Cmax 132 ng/mL (101-196 ng/mL). The Tmax 
was 0.7 h (0.5 – 0.8 h). The short Tmax and absorption half-life (about 0.2 h) shows 
that cetirizine is rapidly absorbed in horses on an empty stomach. This property is 
often correlated to a rapid onset of action. The t½ was about 3.4 h, which indicates 
that steady-state plasma levels are attained by the first day if repeated doses are 
given. Ss is obtained after a delay of 3-5 times the t½ (for cetirizine 9-18.5 h) 
regardless of the dosing interval. Thus, for any drug having a t½ of 4.5 h or less the 
ss will be reached within the first day and a loading dose will not be required in 
this case. The t½ of cetirizine in horse is shorter than the t½ for humans, which is 
approximately  8  h  (Gillard  et  al.,  2005;  Peytavin  et  al.,  2005).  Therefore 
administration twice daily would be appropriate in horse.  
 
Ivermectin (0.2 mg/kg bw) given orally 1.5 h before cetirizine did not affect the 
pharmacokinetics  of  cetirizine.  However,  ivermectin  pre-treatment  12  h  before 
cetirizine  increased  the  AUC  by  60%.  The  Cmax,  t½  and  MRT  also  increased 
significantly following the 12 h pre-treatment. The Tmax for orally administered 
ivermectin is about 3.6 h and the t½ about 3 days (Perez et al., 2002). In this study 
the pre-treatment 1.5 h before cetirizine was assumed to mainly give a local effect 
on the enterocytes as the ivermectin concentration in the intestines should be high 
in  the  intestines  and  low  in  other  tissues.  The  maximum  systemic  effects  of 
ivermectin  would  not  appear  until  after  several  hours.  The  pre-treatment  12  h 
before cetirizine was therefore assumed to have a more systemic effect also on the 
renal  and  bile  excretion.  This  may  explain  why  ivermectin  affects  the 
pharmacokinetics of cetirizine at the 12 h pre-treatment interval but not at the 1.5 h 
pre-treatment  interval.  We  assume  that  the  effect  of  ivermectin  on  the  PK  of 
cetirizine  may  be  related  to  an  inhibition  of  P-gp.  A  mechanism  by  which 
ivermectin might cause elevated plasma levels of cetirizine in horses would be 
increased intestinal uptake, related to inhibition of the P-gp efflux pump in the 
enterocytes. Ivermectin is eliminated mainly by transepithelial intestinal secretion 
(Laffont  et  al.,  2002).  The  enterocytes  will  therefore  be  exposed  to  high 
concentrations of ivermectin both during the absorption and excretion of the drug. 
Inhibition of the P-gp efflux pump would be expected to result in an increased 
uptake  of  cetirizine.  The  contribution  of  the  intestinal  P-gp  to  the  overall 
absorption  of  cetirizine  is  difficult  to  elucidate  without  an  i.v.  study  design. 
However  since  no  effects  on  the  PK  of  cetirizine  were  observed  at  the  1.5 
ivermectin pre-treatment interval one may assume that the effect of ivermectin is  
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not primarily directed towards the intestinal cetirizine absorption. Instead the most 
important  effect  of  ivermectin  on  the  PK  of  cetirizine  may  be  decreased  renal 
excretion. Urinary excretion, which occurs both via active tubular secretion and 
glomerular  filtration,  is  the  major  route  of  cetirizine  elimination  in  humans 
(Benedetti et al., 2001; Bree et al., 2002). The elevated plasma levels may be due 
to  decreased  renal  secretion  and/or  increased  renal  re-absorption  of  cetirizine, 
related to inhibition of the P-gp in the proximal tubular cells of the kidney. To 
discriminate if the effect of ivermectin is directed towards the P-gp activity at the 
renal and/or the intestinal level a study with intravenously administered cetirizine 
would be desirable (no such formulation was found in the market).  
 
No side effects such as drowsiness or gastrointestinal disturbances were noticed 
for any of the horses used in this study. Cetirizine, as well as fexofenadine, is 
known to have insignificant or no anticholinergic effect (Orzechowski, Currie & 
Valancius, 2005; Liu & Farley, 2005). This is important for selection of drugs to 
be used in horses. The pharmacokinetic properties of cetirizine have characteristics 
that are suitable for an antihistamine and this substance may be a useful drug in 
horses. 
 
Effects of the antihistamines and PK/PD modelling (Paper II and 
IV) 
The effects on inhibition of histamine-induced cutaneous wheal formation of the 
histamine H1-antagonist fexofenadine and cetirizine were studied in horses. After 
i.v.  infusion  of  fexofenadine  (paper  II)  at  0.7  mg/kg  bw  and  after  oral 
administration of fexofenadine at 10 mg/kg bw there were a significant decrease in 
histamine-induced wheal formation. After the i.v. administration the maximal effect 
peaked at 2 h with 70 % inhibition and remained over 45 % inhibition for 6 h. 
Significantly decreased values compared to controls were observed at 1, 2, 4 and 6 
h (Dunnet´s post-hoc test; p < 0.05 ). After oral administration of fexofenadine the 
maximal effect peaked at 4 h with about 55 % inhibition. Significant differences 
compared to controls were observed at 4 and 6 h (Dunnet´s post-hoc test; p < 
0.05). In man oral administration of fexofenadine at doses of 40 mg or higher 
inhibited  wheal  and  flare  reactions,  induced  by  intracutaneous  histamine 
provocation, for approximately 12 h (Russell, Stoltz & Weir, 1998) compared to 
the 6 h in horses. This could be explained if the t½ in horse is shorter than in man. 
Since different t½ have been reported in man - 3.5 h (Wang, et al., 2002), 5.1 h 
(van Heeswijk et al., 2006) 6.2 h (Uno et al., 2006) and 10.1 h (Shimizu et al. 
2006)  -  it  is  difficult  to  draw  any  conclusions  from  this.  Following  the  oral 
administration of fexofenadine in horse the Cmax in plasma was about 86 ng/mL 
after dosing at 10 mg/kg bw. In man different Cmax in serum has been  reported: 
160-450  ng/mL  after  a  single  oral  dose  of  about  0.9  to  1.7  mg/kg  bw  of 
fexofenadine (Wang, et al., 2002; Dresser, Kim & Bailey 2005; van Heeswijk et 
al., 2006; Uno et al., 2006; Shimizu et al. 2006). The reported Vd /F in man after a 
single administration was calculated to be 5.6 to 8.9 L/kg (Wang, et al., 2002; van 
Heeswijk et al., 2006; Uno et al., 2006; Shimizu et al. 2006). The Vd/F (calculated 
as dose/AUC*λ) in horse when given 10 mg/kg orally was about 220 L/kg, whilst 
the Varea after i.v. fexofenadine was about 2.7 L/kg which is in the same magnitude  
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as in man. These data together indicate that there is a more effective absorption of 
fexofenadine  in  man  compared  to  horses,  even  tough  the  flip-flop  phenomena 
contributes to the large oral V/F in horse. This allows lower therapeutic doses to be 
used in human medicine. A PK/PD link model indicated that fexofenadine in horse 
has antihistaminic effects at low plasma concentrations. In this model Emax showed 
a range between 55 and 97% and the plasma concentration required to reach EC50 
was about 16 ng/mL. However, oral treatments of horses with fexofenadine may 
not be suitable due to the low bioavailability. 
 
The  PK  and  PD  of  cetirizine  were  studied  following  repeated  oral 
administrations to the horses (paper IV). After three consecutive administrations of 
cetirizine (0.2 mg/kg body weight) every 12 h the trough plasma concentration of 
cetrizine was 16 ± 4 ng/mL (mean ± SD) and the wheal formation was inhibited by 
45 ± 23 %. Then the dose was increased to 0.4 mg/kg bw. After four additional 
administrations every 12 hour the trough plasma concentration was 48 ± 15 ng/mL 
and  the  wheal  formation  was  inhibited  by  68  ±  11%.  The  maximal  observed 
inhibition  of  wheal  formation  was  84  ±  7%  which  occurred  5  h  after  the  last 
administration. Still 11 h after the last administration the inhibition remained over 
55  %  (Dunnet´s  post-hoc  test,  p  <  0.05  for  1,  3,  5,  7  and  11  h  after  last 
administration).  The  t½  was  about  5.8  h.  A  PK/PD  link  model  showed  a  high 
efficacy, the Emax was about 93% and the EC50 about 22 ng/mL. In humans Urien et 
al. (1999) showed an EC50 for wheal inhibition of about 40 ng/ml and an Emax of 
about 60% 3-5 h after an oral dose of 10 mg (approximately 1.4 mg/kg). 
 
The  PK  calculations  for  cetirizine  in  horse  showed  that  the  AUC  was  379 
ng·h/mL (347-453 ng·h/mL) after an administration of 0.2 mg/kg bw. The t½ was 
about 5.8 h, the absorption t½ about 0.23 h and the Tmax about 0.8 h. The short 
absorption  t½  and  the  fast  Tmax  show  that  cetirizine  is  rapidly  absorbed  in  the 
horses. In paper IV cetirizine was given at 12 h-intervals to the horses mixed with 
sugar-beet and there was no restriction of the food-supply during the experiment. 
In our previous study (paper III) with the single dose of cetirizine the drug was 
given via a nasogastric tube and the horses were not fed 12 h before and 3.5 h after 
the administration (although they were bedded on straw). The results of paper IV 
showed that after a dose of 0.2 mg/kg bw the Cmax was lower (58 ng/mL) than in 
the previous study (132 ng/mL), when cetirizine was given as a single dose (paper 
III). On the other hand similar values were observed in the two studies for the 
calculated AUC (379 and 420 ng·h/mL, respectively). In addition the calculated 
median terminal t½ in paper IV was longer (5.8 h) than in paper III (3.4 h). These 
data indicate that food present in the stomach and the proximal intestine will delay 
the  absorption  of  cetirizine,  but  that  the  influence  on  the  total  extent  of  the 
absorption  is  of  minor  importance.  Our  results  showed  low  inter-individual 
variability in plasma concentrations in the horses. This is a characteristic for drugs 
which have limited biotransformation. With reference to this observation one may 
assume  that  cetirizine  in  horse,  like  in  man,  is  metabolised  to  a  relatively  low 
extent.  This  is  advantageous  for  an  antihistamine  since  it  minimises  metabolic 
drug-drug  interactions.  With  regard  to  the  observed  half-life  and  the  observed 
duration of the antihistaminic effect we consider that two daily administrations of 
cetirizine  would  be  suitable  in  horse.  Although  the  absolute  bioavailability  of  
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cetirizine  was  not  assessed,  our  results  indicate  that  the  oral  bioavailability  in 
horses  is  sufficient,  in  contrast  to  the  previously  examined  antihistamines 
clemastine and fexofenadine (Törneke et al., 2003, Olsén et al., 2006). The PK and 
PD  properties  of  cetirizine  have  characteristics  that  are  suitable  for  an 
antihistamine and this substance may be a useful drug in horses. 
 
Adverse reactions to benzylpenicillin (Paper V) 
Case reports of 59 horses reacting adversely to benzylpenicillin in Sweden in 2003-
2005 were obtained through contacts with horse-owners. For the assessment of the 
reports  various  parameters  were  evaluated  such  as  the  times  to  the  reactions, 
information  on  previous  penicillin  treatment,  the  clinical  signs  and  the  actions 
taken in the reacting horses. Among the reports two horses had received sodium or 
potassium  benzylpenicillin  intravenously,  whereas  the  remaining  57  horses  had 
been  treated  with  procaine  benzylpenicillin  intramuscularly.  The  dominance  of 
reactions  for  procaine  benzylpenicillin  over  the  Na/K  salts  of  benzylpenicillin 
correlates  with  previous  reports  in  the  literature  (Marshall,  1980;  Allpress  & 
Heathcote, 1986; Nielsen et al., 1988; Tjälve, 1997).  
 
Allergy  may  underlie  the  adverse  reactions  in  the  horses  given  sodium  and 
potassium  benzylpenicillin  and  also  in  horses  given  procaine  benzylpenicillin. 
However, in most horses in the latter group the clinical signs may be due to toxic 
effects of procaine. In these horses the dominating clinical signs were locomotor 
and  behavioural  changes.  Some  horses  showing  reactions  for  procaine 
benzylpenicillin received continued treatment with the same drug or with a Na/K 
benzylpenicillin  salt  without  problems.  It  appears  that  penicillin  allergy  can  be 
excluded in these cases.  
 
Some  risk  factors  may  enhance  the  probability  that  horses  react  to  procaine. 
Horses  are  more  sensitive  to  procaine  than  humans  (Tobin  et  al.  1977).  This 
implies  that  some  horses  may  be  highly  responsive  to  elevated  plasma 
concentrations  of  procaine.  Procaine  benzylpenicillin  was  previously  used  to  a 
considerable extent in human medicine. Acute adverse reactions were described in 
connection  with  such  treatments  (Hoigné´s  syndrome).  The  patients  suddenly 
expressed extreme fear and had hallucinations and muscle tremor, but there were 
no blood pressure decrease or circulatory collapse. The symptoms appeared during 
or immediately following the administration of procaine benzylpenicillin and are 
probably  caused  by  inadvertent  intravascular  penetration  from  the  muscular 
injection site (Björnberg & Selstam, 1960; Downham et al., 1978; Schreiber & 
Krieg, 2001). Following systemic administration procaine is a relatively specific 
stimulant of the limbic system, which in man can result in a range of emotional and 
somatic  symptoms  similar  to  those  observed  in  Hoigné´s  syndrome  (Servan-
Schreiber et al. 1998). It is known that the limbic system is susceptible to neuronal 
sensitization, implying that there is a gradually increasing response after repetitive 
stimulation over time of sub threshold stimuli, which initially are without effects 
(kindling) (Adinoff et al. 2001). It has been proposed that a kindling mechanism, 
related to repeated injections of procaine benzylpenicillin, may increase the risk for 
Hoigné´s syndrome (Araszkiewicz & Rybakowski, 1996/1997). It is possible that a  
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kindling mechanism may increase the susceptibility to procaine benzylpenicillin 
also  in  horse.  In  the  present  study  30  of  the  horses  reacting  to  procaine 
benzylpenicillin  had  previously  been  treated  with  the  same  drug.  It  has  been 
proposed that the mechanism of kindling may involve cross sensitization to local 
anaesthetics other than procaine (Araszkiewicz & Rybakowski, 1996/1997). It is 
possible that anaesthesia in horses with e.g. lidocaine in connection to previous 
surgical therapy or clinical examination for lameness might increase the sensitivity 
to procaine benzylpenicillin. 
 
Procaine is rapidly hydrolysed by plasma esterases to the non-toxic metabolites 
PABA  and  diethylaminoethanol.  When  high  amounts  of  procaine  enter  the 
circulation the hydrolysing capacity may be exceeded and toxicity occur. Analyses 
of  plasma  esterases  from  reacting  horses  showed  lower  activity  than  in  non-
reacting  control  horses.  Thus,  of  the  amount  of  PABA  formed  at  the  procaine 
hydrolysis in the group of reacting horses was 7.13 ± 1.54 µg/mL (mean ± S.D.), 
whereas in the control group the amount of PABA formed was 8.31 ± 1.22 µg/mL. 
The difference between the two groups was statistically significant (p = 0.003). 
Reduced plasma esterase activity may be one factor that increases the likelihood of 
adverse reactions by delaying the hydrolysis of procaine. It has been reported that a 
group  of  human  patients  who  experienced  systemic  toxic  reactions  to  procaine 
benzylpenicillin  had  significantly  lower  plasma  esterase  activity  compared  to  a 
group of non-reacting patients (Downham et al., 1978). It is concluded that several 
mechanisms may contribute to the adverse reactions of procaine benzylpenicillin in 
horses.  
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Conclusions  
•  In  horse  intestines  CYP3A  mRNA  is  expressed  to  the  highest  extent  in  the 
proximal intestine, with a decreasing gradient toward the distal parts. The mRNA 
expression  is  higher  in  the  proximal  parts  of  the  intestines  than  in  the  liver. 
CYP3A-enzyme  activity  increased  slightly  from  the  proximal  to  the  distal 
duodenum and the proximal jejunum, followed by a plateau in the other parts of 
jejunum  and  a  decrease  towards  ileum  caecum,  and  colon.  CYP3A-protein  is 
localised intracellularly of the enterocytes. CYP3A in the small intestine may play 
a major role in the first-pass metabolism of drugs, which are substrates for these 
CYP-enzymes.  
 
• Fexofenadine has antihistaminic effects at low plasma levels in horse. However, 
oral  treatment  of  horses  with  fexofenadine  is  not  suitable  due  to  low 
bioavailability. The oral bioavailability of fexofenadine was significantly decreased 
when  the  horses  were  pre-treated  with  ivermectin  before  the  fexofenadine 
administration.  However,  ivermectin  did  not  affect  the  pharmacokinetics of i.v. 
administered fexofenadine. The mechanism underlying the effects of ivermectin on 
the pharmacokinetics of fexofenadine is unclear, but may be related to inhibition of 
the OATP influx pump in the intestinal mucosa. 
 
• The pharmacokinetic and pharmacodynamic properties of cetirizine in horse have 
characteristics that are suitable for an antihistamine. The maximal inhibition of 
histamine-induced  wheal  formation  was  satisfactory  and  long  lasting.  Oral 
administrations  of  cetirizine  in  doses  of  0.2-0.4  mg/kg  given  at  12  h  intervals 
would be adequate to exert significant antihistaminic effects and this drug may be a 
useful antihistamine in equine medicine. Ivermectin administered at a 12 h pre-
treatment interval, resulted in increased AUC, Cmax, t½β and MRT of cetirizine in 
the  horses.  This  effect  may  mainly  be  related  to  decreased  renal  excretion  of 
cetirizine due to inhibition of P-gp in the proximal tubuli of the kidney.  
 
• Acute adverse reactions to benzylpenicillin were much more frequent in horses 
treated  with  procaine  benzylpenicillin  than  with  potassium  or  sodium 
benzylpenicillin.  The  dominating  clinical  signs  in  horses  reacting  to  procaine 
benzylpenicillin were locomotor and behavioural changes, which occurred during 
the injections or within one minute after the injections. Allergy may underlie some 
of the adverse reactions, but in the majority of cases the clinical signs may be due 
to toxic effects of procaine. Several mechanisms may contribute to the toxicity of 
procaine. Low plasma esterase activity may increase the likelihood for procaine 
toxicity and constitute one risk factor.  
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Future perspectives 
The results of this thesis indicate that in horse the intestinal mucosa is an important 
site of first-pass metabolism of drugs and other xenobiotics due to the high levels 
of CYP3A-enzymes in this tissue. Further studies to explore the consequences of 
CYP3A-related  metabolism  in  the  horse  intestines  on  the  disposition  of  drugs 
would be of interest.  
 
It appears that there are only a few CYP-enzymes belonging to the families 1, 2 
and 3 that are responsible for drug metabolism and thus involved in drug-drug 
interactions. It would be of interest to examine additional CYP-enzymes such as 
CYP2D6, CYP2E and also CYP1A and CYP2C in the intestines in horses.  
 
It  would  be  of  interest  to  explore  the  occurrence  of  Phase  II  enzymes  in  the 
intestines of horse. 
 
The result showed that cetirizine can be a useful antihistamine in horse. IgE and 
mastcell activation are involved in the pathogenesis of several disorders in horse, 
such  as  equine  heaves,  chronic  bronchitis/bronchiolitis,  chronic  obstructive 
pulmonary disease/recurrent airway obstruction and the syndrome called “sweet 
itch”, “summer eczema” or “allergic urticaria” (a worldwide chronic seasonally 
recurrent pruritic allergic skin disease in horses). In addition IgE and mast cell 
activation are involved in allergic reactions to venoms and other antigens and in 
anaphylactic reactions to drugs. Extended studies to explore the therapeutic value 
of cetirizine in such conditions in horse would be of interest. 
 
It  is  known  that  an  atypical  form  of  plasma  esterase  exists  in  humans 
(polymorphism). It would be of interest to examine if a similar polymorphism in 
procaine  hydrolysing  plasma  esterases  exists  in  horses,  including  studies  on 
possible differences between different breeds. 
 
It  would  be  of  interest  to  further  explore  the  incidence  by  which  allergy  may 
underlie the adverse reactions to benzylpenicillin. For this purpose it would be 
valuable to have an allergy test against benzylpenicillin which can be applied to 
blood samples.  
 
It would be of interest to do a follow-up study to see if there will be a declining 
number of adverse reactions to benzylpenicillin if benzylpenicillin derivatives with 
long duration but without procaine content will become available on the market. 
Such  a  formulation,  consisting  of  benzylpenicillin  with  an  ester-binding  to 
diethylaminoethanol, is already available for cattle.  
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Populärvetenskaplig sammanfattning 
Om hästen blir sjuk är det viktigt att den får rätt medicindos för att få bukt med 
sjukdomen och utan att den får biverkningar. Att förstå detaljerna om de funktioner 
som styr hur kroppen tar hand om ett läkemedel är viktigt både för den enskilda 
hästen och för arten. För att veta hur mycket och vilken slags medicin man ska ge 
till sin häst för att få den bästa effekten måste man veta hur läkemedlen verkar och 
hur hästar tar upp, bryter ned och utsöndrar de olika substanserna. Effekten av en 
medicin beror av hur kroppens organ och vävnader fungerar och samspelar när de 
påverkas av ett läkemedel.  
 
Två  viktiga  faktorer  som  påverkar  upptaget  av  medicinerna  är  enzymer  och 
transportproteiner. I tarm och lever sker nedbrytningen med hjälp av metaboliska 
enzymer.  Dessa  enzymer  avgör  hur  fort  läkemedlet  omsätts  i  kroppen.  Vi  har 
undersökt  ett  så  kallat  cytokrom  P450  3A-enzym  (CYP3A),  var  det  finns,  hur 
aktivt  det  är  samt  hur  de  gener  som  kodar  för  enzymet  uttrycks. 
Transportproteinerna  kan  ”knuffa  ut”  medicinerna  så  att  de  inte  kan  verka  i 
kroppen eller så kan de underlätta att medicinerna tas in i kroppen, så att de blir 
mer  aktiva.  I  tarmen  kan  hastigheten  för  upptag  och  utsöndring  av  medicinen 
variera dels beroende av om man samtidigt äter mat eller något annat läkemedel 
dels beroende av olika transportproteiner och enzymer som sitter i tarmväggen. 
Transportproteinerna har också stor betydelse för hur medicinen förs från tarmen 
till  blodet  och  vidare  ut  i  hela  kroppen.  Både  enzymer  och  transportproteiner 
påverkar därför tillsammans hur mycket medicin som kommer ut i hästens kropp. 
Ett sätt att undersöka detta är att mäta hur hög koncentration av medicin som finns 
i  blodet.  Vi  har  undersökt  vad  som  händer  om  man  påverkar  effekten  av  ett 
transportprotein  som  kallas  P-glykoprotein  (P-gp)  på  upptaget  av  två  olika 
läkemedel hos häst.  
 
Det är dock inte bara enzymer och transportproteiner som påverkar effekten av 
olika  mediciner  och  ibland  kan  hästarna  drabbas  av  biverkningar  som  inte  har 
direkt  samband  med  de  ovan  nämnda  faktorerna.  Läkemedelsbiverkningar  kan 
indelas i sidoeffekter, överdoseffekter, allergier, förändringar i mikrofloran i mage 
och  tarm,  interaktioner  (med  andra  läkemedel,  mat,  naturmedel  mm), 
överkänslighet  på  grund  av  ärftliga  orsaker  (så  kallad  idiosynkrasi),  lokala 
skadeeffekter,  carcinogena  effekter  eller  verkan  på  det  ofödda  fostret 
(teratogenicitet).  
 
I samband med behandling av hästar med penicillinprokain förekommer att de 
drabbas av så kallad penicillinchock. Reaktionerna kan vara relativt lindriga, såsom 
hudreaktioner,  eller  att  hästarna  stelnar  till  under  en  kort  stund,  till  allvarliga 
reaktioner då de ramlar ihop under kramper. Även dödsfall förekommer. Dessa 
reaktioner kommer oftast under injektionen eller strax efter avslutad injektion. Vi 
har sökt orsaken till varför behandling med penicillin kan ge chock hos hästar. Vi 
har  undersökt  hästarnas  förmåga  att  bryta  ned  prokain.  En  dålig 
nedbrytningsförmåga kan leda till att prokainet blir en toxiskt (giftigt).  
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I den första delstudien i avhandlingen undersökte vi enzymet CYP3A i tarmen 
hos  häst.  Vi  samlade  in  vävnadsprover  från  slaktmaterial.  Genuttryck  och 
enzymaktivitet studerades med olika biokemiska metoder. Vi tittade också på var 
och  i  vilka  celler  i  tarmen  enzymet  finns.  Detta  undersökte  vi  med 
immunohistokemi.  Det  högsta  uttrycket  av  CYP3A-genen  fanns  i  början  av 
tunntarmen  och  sedan  sjönk  nivån  i  riktning  mot  tjocktarmen.  Aktiviteten  hos 
enzymet följde i stort sett uttrycket av genen för enzymet i de olika delarna av 
tarmen.  De  celler  som  innehöll  CYP3A  fanns  främst  ytligt  i  slemhinnan  i 
tarmväggen. Resultaten visar att läkemedel givna via munnen kan brytas ned av 
CYP3A redan i tarmcellerna.  
 
I två andra delstudier har vi tittat på antihistaminer till häst. Användning av s.k. 
antihistaminer för att lindra allergier i framför allt övre luftvägarna hos människa är 
mycket utbredd. Antihistaminer används även till människor för att lindra klåda. 
Tidigare  undersökningar  av  olika  typer  av  antihistaminer  till  häst  har  visat  att 
hästar  inte  tar  upp  dessa  mediciner  från  mage/tarm  speciellt  bra.  Ett  bra 
antihistamin  till  häst  ska  vara  effektivt  och  ta  bort  eller  åtminstone  dämpa  de 
allergiska  besvären.  Det  ska  helst  vara  snabbverkande.  Det  ska  ha  en  god 
biotillgänglighet, när man ger medicinen via munnen, det vill säga det ska tas upp i 
kroppen så att det kan göra verkan. Det får gärna vara verksamt under en lång tid 
så  att  man  slipper  medicinera  flera  gånger  per  dag.  Det  ska  inte  påverka  eller 
påverkas av andra läkemedel. Det bör heller inte ha några svårare biverkningar. 
Man vill t ex inte ha en trött häst eller en som har problem med magen och får 
kolik. Syftet med dessa undersökningar var att hitta ett bra antihistamin som passar 
att ges via munnen till häst. Vi har tittat på två olika antihistaminer, fexofenadin 
och cetirizin, för att ta reda på om de går att använda till häst.  
 
Allergiska problem kan vara ett användningsområde för antihistaminer till häst. 
Vid kontakt med främmande ämnen kan immunsystemet bilda en typ antikroppar 
som  kallas  immunglobulin  av  E-typ  (IgE).  IgE  finns  i  mycket  små  mängder  i 
kroppens  vätskor  och  har  förmåga  att  sätta  sig  fast  på  speciella  celler  såsom 
mastceller  och  vissa  typer  av  vita  blodkroppar.  Mastcellerna  finns  utspridda  i 
kroppens vävnader. Dessa celler innehåller ett flertal biologiskt aktiva ämnen som 
orsakar  kraftig  inflammation  och  klåda.  Om  en  allergiframkallande  substans 
(allergen; ämnet som utlöst bildning av IgE-antikroppar) kommer i kontakt med 
IgE-antikroppar  och  detta  sker  på  mastcellens  yta,  frigörs  aktiva  ämnen  från 
mastcellen såsom histamin. Lokalt uppstår då en kraftig inflammation med svullnad 
och rodnad i vävnaden. Histaminet som frisätts ger även en intensiv klåda.  
 
Ett tillstånd som man anser ha samband med histamin och IgE-reaktion hos häst 
är ”sommareksem”. Sommareksem är ett stort problem för många hästar och deras 
ägare. Detta är en allergisk hudreaktion (dermatit) som ofta uppstår av allergi mot 
betten  från  svidknott  (Culicoides  spp).  Även  insektsbett  från  myggor  eller 
allergiframkallande  ämnen  i  luft  och  foder  kan  ligga  bakom  reaktionerna. 
Utvecklingen av allergi antas bero dels av moderns antikroppsöverföring till fölet, 
dels  på  genetisk  disposition  samt  kraftig  exponering  för  allergi-framkallande 
ämnen. För att hindra angrepp kan man försöka att hålla knotten borta genom att  
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stalla in hästarna, använda ”knottfria” beten (undvika låglänta och sanka marker) 
och/eller använda täcken. Som en del i detta kan också ingå att hålla hästen ren och 
använda insektsrepellerande medel. Det finns en mängd olika salvor, liniment och 
huskurer som används där vissa avser att hålla insekterna borta medan andra anses 
lindra eller förhindra uppkomst av inflammation men inga kontrollerade studier 
finns utförda. Ett läkemedel som används till häst för att minska inflammationen är 
kortison.  
 
För att undersöka antihistaminerna gavs i våra undersökningar medicinerna till 
ett antal hästar. Blodprover togs med olika intervall både före det att hästarna fått 
medicinerna  och  flera  gånger  efter,  oftast  åtminstone  upp  till  ett  dygn  efter 
medicineringen. Halterna av medicinerna i blodet mättes och korrelerades till den 
tid som förflutit sedan medicineringen. Effekterna av medicinerna mättes via ett 
”pricktest”. Man ger då histamininjektioner in i huden. Då uppstår en kvaddel som 
är  en  hastigt  uppträdande,  välavgränsad  röd  upphöjning  i  huden.  Kvaddeln 
uppkommer genom att vätska läckt ut från de små blodkärlen till bindväven. Vi 
mätte  kvaddelarna  och  beräknade  deras  area.  Som  positiv  kontroll  användes 
histamininjektioner  före  medicineringen  och  som  negativ  kontroll  användes 
fysiologisk koksalt. 
 
I det ena försöket var det fem hästar som först fick en dos fexofenadin (Telfast) 
10 mg/kg via munnen (oralt) och vid ett annat tillfälle fick de 0,7 mg/kg intravenöst 
(i.v.), i ett s.k. crossover-försök. Vi tog sedan upprepade blodprover och vi gjorde 
även histamintester efter medicin-givan. Resultaten visade att man fick en effekt 
(dvs en hämning av storleken av kvaddlarna) på 55% vid oral giva och detta varade 
i ca 4 timmar. Intravenöst var effekten 70% och den kvarstod i 6 timmar. Den 
högsta halten av fexofenadin uppmättes 1 timme och 15 min efter tillförseln av 
fexofenadin.  Då  var  koncentrationen  fexofenadin  i  blodet  86  ng/ml. 
Halveringstiden (tiden som det tar att halvera halten i blodet) var 5 timmar för oral 
giva  och  2,4  timmar  för  iv.  Tyvärr  var  biotillgängligheten  (dvs  den  mängd 
fexofenadin som togs upp i kroppen) väldigt låg, bara 2,6 %, vilket innebär att 
hästarna bara kunde tillgodogöra sig läkemedlet i mycket liten grad. 
 
Vi  gjorde  då  ett  försök  med  cetirizin  (Cetirizin).  Detta  försök  hade  ett  lite 
annorlunda upplägg. Sex hästar fick flera givor av substansen; två gånger dagligen, 
7 ggr totalt. Först fick de tre doser med 0,2 mg/kg; sedan dubbleras dosen de sista 
4 gångerna. Vi tog både blodprov och ”pricktest” var 12:e timme, precis innan de 
fick en ny medicindos. Detta innebär att vi mätte de lägsta blodnivåerna. Efter 3 
doser med 0.2 mg/kg (efter 36 timmar) hämmades kvaddlarnas storlek med 45%. 
Koncentrationen i blodet var då 16 ng/ml. Efter ytterligare tre doser med 0.4 mg/kg 
(efter  72  timmar)  hämmades  kvaddlarnas  storlek  med  68%. 
Medicinkoncentrationen i blodet var då 48 ng/ml. Vi följde sedan upp med tätare 
prover efter sista dosen. Den största effekten kom 5 timmar senare och hämningen 
av kvaddelstorlekarna var då 84%. Vad gäller upptaget av cetirizin från tarmen så 
såg det också bra ut. Högsta halten uppmättes efter knappt en timme och var då 
132 ng/ml. Halveringstiden var knappt 6 timmar. Sammanfattningsvis så verkar 
cetirizin  vara  ett  bra  antihistamin  till  häst.  Hästarna  tar  upp  tillräckligt  av 
läkemedlet och det går bra att ge det i fodret. I doser på 0,2-0,4 mg/kg hindrar det  
55 
reaktionerna vid ”pricktest” med histamin i minst 11 timmar. Det bör därför ges två 
gånger dagligen för att vara så effektivt som möjligt.  
 
I samband med undersökningarna med fexofenadin och cetirizin gjorde vi också 
studier av vad som händer om man påverkar  transportproteinet P-gp. Vi vet sedan 
tidigare  att  både  fexofenadin  och  cetirizin  transporteras  med  hjälp  av  dessa 
proteiner. Vi ville ta reda på om läkemedlens omsättning i hästen kan förändras av 
att  man  förbehandlar  eller  samtidigt  ger  ett  annat  läkemedel  som  också 
transporteras av P-gp. Vi valde då ivermektin som är ett vanligt förekommande 
avmaskningsmedel till häst och som dessutom transporteras med hjälp av P-gp. 
Eftersom man kan anta att P-gp har fullt upp med att ta hand om ivermektin så bör 
halten  av  antihistamin  i  blodet  bli  påverkat  om  man  har  förbehandlat  med 
ivermektin. 
 
I den ena studien gav vi 0,2 mg/kg ivermectin (Noromectin) 12 timmar innan de 
fick  fexofenadin.  Med  hjälp  av  blodprovsanalyser  såg  vi  att  hästarna  tog  upp 
fexofenadin ännu sämre än tidigare då de var förbehandlade med ivermectin. Det är 
oklart vad detta beror på. Det kan vara så att P-gp inte har så stor betydelse i det 
här  fallet  utan  att  andra  transportproteiner  som  istället  underlättar  upptaget  av 
fexofenadin över tarmslemhinnan har större betydelse.  
 
I den andra studien fick hästarna också 0,2 mg/kg ivermektin, antingen 1,5 eller 
12 timmar innan de fick cetirizin. Det visade sig att det inte blev någon effekt om 
man  gav  ivermectin  1,5  timmar  före  cetirizingivan.  Däremot  ökade  cetirizin 
upptaget till blodet med 60 % om man gav ivermectin 12 timmar före cetirizin. 
Även om både koncentrationen i blodet och det totala upptaget till blodet ökade så 
såg vi inga oönskade effekter av cetirizinet, såsom t ex trötthet eller påverkan på 
tarmarna. Cetirizin är ett vanligt använt antihistamin till människa och där vet man 
att  man  kan  ta  flera  gånger  den  rekommenderade  dosen  utan  att  man  får 
biverkningar. Detta verkar gälla även för häst. 
 
I  den  sista  delstudien  undersökte  vi  ”penicillinchock”  hos  häst. 
Penicillinbehandling av häst är mycket vanligt förekommande. Penicillin till häst 
ges alltid via spruta. Antingen ges ett vattenlösligt penicillinsalt, oftast i.v eller ett 
svårlösligt  salt  av  penicillin  och  prokain  i  en  muskel  (i.m).  Ofta  görs 
medicineringen i en muskel av djurägaren eller en annan skötare. Att ge hästar 
penicillin via munnen som hos människa, hund och katt, är inte lämpligt eftersom 
hästar inte tar upp penicillin från tarmen till blodet speciellt bra och det finns även 
risk för att tarmfloran i påverkas. Vanligtvis tål hästarna penicillin väldigt bra men 
i sällsynta fall kan de få en penicillinchock. Reaktionerna ses som regel efter i.m. 
injektioner av penicillinprokain, men ibland ses de även efter i.v. injektioner av de 
vattenlösliga  penicillinsalterna.  Hästarna  reagerar  i  omedelbar  anslutning  till 
injektionerna  med  oro,  svettningar  och  balansrubbningar  och  ibland  ramlar  de 
omkull. De återhämtar sig sedan oftast inom loppet av cirka en halvtimme, men i 
värsta fall kan de dö inom några minuter. 
 
Det finns flera tänkbara mekanismer bakom dessa reaktioner. En möjlighet är att 
det är fråga om en allergi mot penicillin. För penicillinsalter som sprutats i.v. kan  
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man anta att allergi är orsaken. För penicillinprokain är det även möjligt att det är 
fråga om en toxisk reaktion mot prokain. Vid i.m. injektion av penicillinprokainet 
sker en långsam upplösning av saltet från muskeldepån.  
 
Prokainets uppgift är att fördröja upptaget av penicillinet från injektionsplatsen. 
Utan prokain skulle man annars behöva spruta hästen var åttonde timma under 
behandlingsperioden. Med prokain räcker det med en dos dagligen. Om man vill ge 
ett vattenlösligt penicillinsalt ska det även ges direkt i blodet, vilket som regel 
kräver att hästen är inskriven på en klinik. Prokainet verkar också lokalbedövande 
på  injektionsstället,  vilket  är  positivt  för  hästen.  Om  preparatet  skulle  komma 
direkt ut i blodet kan det leda till skadliga effekter på grund av att halten fritt 
prokain i blodet blir för hög. Hästar är känsliga för prokain och man kan tänka sig 
att de reagerar p.g.a. prokaintoxicitet. Hästen kan då bli orolig, få svettningar och 
kramper.  I  normalfallet  bryts  prokainet  ner  till  ofarliga  beståndsdelar  i  blodet. 
Nedbrytningen av prokain sker med hjälp av enzymer, så kallade esteraser. En 
möjlighet som diskuteras är att vissa hästar skulle kunna ha en låg aktivitet av 
esteras  i  blodet.  Detta  skulle  kunna  disponera  dem  för  att  drabbas  av 
prokaintoxicitet. Det finns också beskrivet att man kan bli extra känslig för prokain 
(och andra lokalbedövningsmedel) efter upprepade injektioner.  
 
Vi  har  tittat  på  59  fall  där  hästar  drabbats  av  någon  form  av  reaktion  vid 
behandling  av  penicillin.  Hästarnas  reaktioner  varierade  kraftigt  -  från  ganska 
lindriga, såsom nässelutslag - till mycket våldsamma neurologiska reaktioner där 
hästarna slängde sig handlöst i boxen och tycktes vara helt okontaktbara. De flesta 
hästarna  reagerade  snabbt  efter  injektionerna.  I  studien  har  vi  även  undersökt 
esterasaktiviteten i blodet hos hästar som har fått en penicillinchock och jämfört 
dessa  med  hästar  som  inte  har  reagerat.  Det  visade  sig  då  att  hästar  med  låg 
esterasaktivitet var betydligt överrepresenterade i chockgruppen. En dålig förmåga 
att bryta ned prokain kan vara en faktor som bidrar till att hästen har en ökad risk 
att drabbas av penicillinchock. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Haec satis sunt dicta nobis 